Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study

Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study

Introduction The prevalence of arthropathy in moderate haemophilia A (MHA) and B (MHB) is not well known. Aim We evaluated joint health in Nordic patients in relation to their treatment modality. Methods A cross‐sectional, multicentre study covering MHA and MHB in Sweden, Finland and Norway. Arthrop...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Haemophilia : the official journal of the World Federation of Hemophilia 2020-09, Vol.26 (5), p.891-897
Hauptverfasser: Måseide, Ragnhild J., Berntorp, Erik, Astermark, Jan, Olsson, Anna, Bruzelius, Maria, Frisk, Tony, Nummi, Vuokko, Lassila, Riitta, Tjønnfjord, Geir E., Holme, Pål A.
Format: Artikel
Sprache:eng
Schlagworte:
Age
arthropathy
Clinical Medicine
Coagulation factors
Factor VIII deficiency
Hematologi
Hematology
Hemophilia
joint score
Klinisk medicin
Medical and Health Sciences
Medicin och hälsovetenskap
moderate haemophilia A
moderate haemophilia B
Patients
Phenotypes
Prophylaxis
Surgery
Ultrasound
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction The prevalence of arthropathy in moderate haemophilia A (MHA) and B (MHB) is not well known. Aim We evaluated joint health in Nordic patients in relation to their treatment modality. Methods A cross‐sectional, multicentre study covering MHA and MHB in Sweden, Finland and Norway. Arthropathy was evaluated by ultrasound (HEAD‐US) and Haemophilia Joint Health Score (HJHS). Results We report on 145 patients: median age 28 years (IQR 13‐52) and 61% MHA. Baseline factor VIII/factor IX activity (FVIII/FIX:C) was 2 IU/dL (median) (IQR 2‐4): lower for MHB (2 IU/dL, IQR 1‐2) than MHA (3 IU/dL, IQR 2‐4) (P 
ISSN:1351-8216
1365-2516
DOI:10.1111/hae.14114